Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

Blood

Volumn 111, Issue 2, 2008, Pages 785-789

  Dispenzieri, Angela ^a   Kyle, Robert A ^a   Katzmann, Jerry A ^a   Therneau, Terry M ^a   Larson, Dirk ^a   Benson, Joanne ^a   Clark, Raynell J ^a   Melton III, L Joseph ^a   Gertz, Morie A ^a   Kumar, Shaji K ^a   Fonseca, Rafael ^b   Jelinek, Diane F ^c   Rajkumar, S Vincent ^a  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; M PROTEIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CONFIDENCE INTERVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; RISK ASSESSMENT; SMOLDERING MULTIPLE MYELOMA;

EID: 38349136782     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-08-108357     Document Type: Article

References (28)

1. Kyle RA, Greipp PR. Smoldering multiple myeloma. New Engl J Med. 1980;302:1347-1349.
2. Alexanian R, Barlogie B, Dixon D. Prognosis of asymptomatic multiple myeloma. Arch Intern Med. 1988;148:1963-1965.
3. Dimopoulos MA, Moulopoulos A, Smith T, Delasalle KB, Alexanian R. Risk of disease progression in asymptomatic multiple myeloma. Am J Med. 1993;94:57-61.
4. Facon T, Menard JF, Michaux JL, et al. Prognostic factors in low tumour mass asymptomatic multiple myeloma: a report on 91 patients: The Groupe d'Etudes et de Recherche sur le Myelome (GERM). Am J Hematol. 1995;48:71-75.
5. Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol. 2002;20:1625-1634.
6. Weber DM, Dimopoulos MA, Moulopoulos LA, Delasalle KB, Smith T, Alexanian R. Prognostic features of asymptomatic multiple myeloma. Br J Haematol. 1997;97:810-814.
7. Rosinol L, Blade J, Esteve J, et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol. 2003;123:631-636.
8. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.
9. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-569.
10. Kyle RA, Remstein E, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356:2582-2590.
11. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812-817.
12. Dingli D, Kyle RA, Rajkumar SV, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood. 2006;108:1979-1983.
13. Dispenzieri A, Lacy MQ, Katzmann JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2006;107:3378-3383.
14. Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol. 2007;137:240-243.
15. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001;47:673-680.
16. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437-1444.
17. Therneau TM, Gronbach PM. Modeling survival data: extending the Cox model. New York: Springer-Verlag; 2000:120-126.
18. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc Ser B. 1972;34:187-220.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JAMA. 1958;53:457-481.
20. Peto R, Peto J. Asymptotically efficient rank invariant procedures (with discussion). J R Stat Soc [Ser A]. 1972;135:185-207.
21. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706.
22. Kumar S, Fonseca R, Dispenzieri A, et al. High incidence of IgH translocations in monoclonal gammopathies with abnormal free light chain levels [abstract]. Blood. 2006;108:3514a.
23. Waldenström J. Studies on conditions associated with disturbed gamma globulin formation (gammopathies). Harvey Lect. 1961;56:211-231.
24. Waldenstrom J. [Benign and malignant monoclonal hypergammaglobulinemia (gammopathy)]. Schweiz Med Wochenschr. 1970;100:290-296.
25. Kyle RA. "Benign" monoclonal gammopathy: a misnomer? JAMA. 1984;251:1849-1854.
26. Kyle RA. Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am J Med. 1978;64:814-826.
27. Alexanian R. Localized and indolent myeloma. Blood. 1980;56:521-525.
28. Gonzalez-Paz N, Chng WJ, McClure RF, et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood. 2007;109:1228-1232.